Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
Healthcare
$39.15 +8.79%
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
52W Low $23.00High $36.61
Volume 0.30M
Average 0.34M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$70.12M
FY 2025 · Annual
Net Income
-$63.91M
FY 2025 · Annual
Income Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 59.63M |
| Selling, General & Admin | 10.49M |
| Operating Expenses | 70.12M |
| Depreciation & Amortization | 304K |
| EBITDA | (69.82M) |
| EBITDA Margin | — |
| Operating Income | (70.12M) |
| Operating Margin | — |
| Interest Income | 1.97M |
| Interest Expense | 0 |
| Other Income / Expenses | 5.98M |
| Income Before Tax | (64.14M) |
| Pre-Tax Margin | — |
| Income Tax Expense | (227K) |
| Net Income | (63.91M) |
| Net Margin | — |
| EPS (Basic) | (2.33) |
| EPS (Diluted) | (2.33) |
| 27.44M | |
| 27.44M |
COAG Earnings Waterfall · TTM
NASDAQ:COAG · Revenue to Net Income
No earnings data available.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 25, 2026 |
How much revenue does COAG generate?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported $0.00 of revenue in fiscal 2025.
Is COAG profitable?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) reported -$63.91M of net income.
Continue the stock analysis
Jump to another research area for this company.